Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 87
Filter
1.
Rev. cuba. hematol. inmunol. hemoter ; 36(3): e1277, jul.-set. 2020. tab, graf
Article in Spanish | LILACS, CUMED | ID: biblio-1156444

ABSTRACT

Introducción: La aplasia medular adquirida grave es una enfermedad hematológica infrecuente caracterizada por una disminución o ausencia de precursores hematopoyéticos en la médula ósea, lo cual se expresa con distintos grados de citopenias. Varios factores, infecciosos o no, pueden incidir en su origen. Su manejo es complejo y puede incluir tratamiento inmunosupresor y trasplante de progenitores hematopoyéticos alogénico. Objetivo: Demostrar la utilidad de la realización del trasplante de progenitores hematopoyéticos alogénico haploidéntico en pacientes con aplasia medular grave. Caso clínico: Paciente masculino de 21 años de edad, con antecedentes de salud, que en octubre del 2018 debutó con íctero, pancitopenia, lesiones purpúrico hemorrágicas en piel y mucosas, en el curso de una hepatitis aguda seronegativa. La biopsia de médula ósea mostró aplasia medular severa. Se inició tratamiento inmunosupresor con globulina antitimocίtica, ciclosporina A y metilprednisolona. Al cabo de los 6 meses mantenía trombocitopenia severa con necesidades transfusionales y en octubre de 2019 se decide realizar trasplante de progenitores hematopoyéticos alogénico con donante haploidéntico y empleando como tratamiento acondicionante globulina antitimocίtica, fludarabina, ciclofosfamida y bajas dosis de irradiación corporal total. En evaluación clίnica de julio de 2020 (dίa + 280 del trasplante) el paciente estaba asintomático y con parámetros hematológicos normales. Conclusiones: Se demostró que el trasplante de progenitores hematopoyéticos alogénico haploidéntico es un proceder realizable y útil en pacientes con aplasia medular grave, lo cual corrobora el beneficio clínico que puede aportar su ejecución en pacientes con esta enfermedad(AU)


Introduction: Acquired severe marrow aplasia is a rare hematological disease characterized by decrease or absence of hematopoietic precursors in bone marrow, which is expressed with different degrees of cytopenias. Several factors, infectious or not, can influence its origin. Its management is complex and may include immunosuppressive treatment and allogeneic hematopoietic stem-cell transplantation. Objective: To demonstrate the usefulness of performing haploidentical allogeneic hematopoietic stem-cell transplantation in patients with severe medullary aplasia. Clinical case: A 21-year-old male patient, with medical history, who first presented, in October 2018, with icterus, pancytopenia, as well as purpuric hemorrhagic lesions on the skin and mucosa, in the course of acute seronegative hepatitis. The bone marrow biopsy showed severe marrow aplasia. Immunosuppressive treatment was started with antithymocytic globulin, cyclosporine A, and methylprednisolone. After six months, he maintained severe thrombocytopenia under transfusion requirements and, in October 2019, the decision was to perform allogeneic hematopoietic stem-cell transplantation with a haploidentical donor and using antithymocyte globulin, fludarabine, cyclophosphamide, and low doses of total body irradiation as conditioning treatment. In the clinical assessment carried out in July 2020 (day +280 after transplantation), the patient was asymptomatic and with normal hematological parameters. Conclusions: Transplantation of haploidentic allogeneic hematopoietic progenitors was shown to be a feasible and useful procedure in patients with severe marrow aplasia, which corroborates the clinical benefit that its execution can bring in patients with this disease(AU)


Subject(s)
Humans , Male , Young Adult , Tissue Donors/ethics , Methylprednisolone/therapeutic use , Whole-Body Irradiation/methods , Microscopy, Electron, Scanning Transmission/methods , Hematologic Diseases , Hematopoietic Stem Cell Transplantation/methods , Cuba , Transplantation, Haploidentical/methods , Anemia, Aplastic/therapy , Antilymphocyte Serum
2.
Gac. méd. Méx ; 156(3): 188-194, may.-jun. 2020. tab, graf
Article in English, Spanish | LILACS | ID: biblio-1249893

ABSTRACT

Resumen Introducción: Después de un trasplante de células progenitoras hematopoyéticas (TCPH), la reconstitución de las células natural killer (NK) es la principal barrera contra las infecciones virales. Objetivo: Determinar que el conocimiento sobre la cinética de la reconstitución de las células NK posterior al TCPH contribuye a un eficiente monitoreo del trasplante, lo que incrementa la posibilidad de éxito de este. Método: Se incluyeron 21 pacientes sometidos a TCPH, así como un grupo control de individuos clínicamente sanos. En diferentes momentos después del trasplante (intervalo de 21 a 670 días), mediante citometría de flujo se cuantificaron las células NK CD3− CD16+ CD56+ en muestras de sangre periférica. Resultados: La recuperación de las células NK ocurre entre los tres y seis meses y entre los 10 y 12 meses postrasplante; su número fue significativamente menor (en comparación con el grupo control) en el tiempo restante del monitoreo. Conclusiones: El primer periodo de recuperación de las células NK ocurre entre los tres y seis meses posteriores al trasplante. La reconstitución es transitoria y el número de células NK varía en los primeros años.


Abstract Introduction: After hematopoietic stem cell transplantation (HSCT), natural killer (NK) cells reconstitution is the main barrier against viral infections. Objective: To determine that the knowledge on the kinetics of NK cell reconstitution after HSCT contributes to transplant efficient monitoring, which increases the possibility of its success. Method: Twenty-one patients undergoing HSCT were included, as well as a control group of clinically healthy individuals. At different time points after transplantation (range of 21 to 670 days), CD3- CD16+ CD56+ NK cells were quantified by flow cytometry in peripheral blood samples. Results: NK cell recovery occurs at three to six months and 10 to 12 months post-transplantation; their number was significantly lower (in comparison with the control group) in the rest of the monitoring time. Conclusions: The first period of NK cell recovery occurs between three and six months after transplantation. Reconstitution is transient and the number of NK cells varies in the first years.


Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Killer Cells, Natural/cytology , Hematopoietic Stem Cell Transplantation/methods , Time Factors , Prospective Studies , Receptors, IgG , CD3 Complex , CD56 Antigen , GPI-Linked Proteins , Flow Cytometry
3.
Rev. chil. pediatr ; 91(2): 226-231, abr. 2020. tab
Article in Spanish | LILACS | ID: biblio-1098895

ABSTRACT

Resumen: Introducción: La sangre de cordón umbilical (SCU) como fuente para trasplante de células proge- nitoras hematopoyéticas (TPH) está bien establecida. Internacionalmente, menos del 10% de los TPH de SCU corresponde a donantes hermanos compatibles. Dentro de la red del Programa Infantil Nacional de Drogas Antineoplásicas (PINDA), existe desde enero 2004 un programa de donación dirigida de SCU para TPH. Pacientes y Método: Se diseñó un estudio observacional, retrospectivo, descriptivo, se revisaron el número y características de las unidades de SCU recolectadas en el PINDA y el número, características y evolución de los pacientes trasplantados con esas unidades entre enero de 2004 y octubre de 2018. Resultados: Sesenta unidades de SCU han sido recolectadas, de ellas 55 con registro completo. La mediana de volumen de las unidades almacenadas fue 74,8 ml (30,0-170,8), la mediana de células nucleadas totales 7,6 x 10e8 (2,0-21,1), mediana de células CD34+ 1,6 x 10e6 (0,2-11,6). Cuatro pacientes con leucemias de alto riesgo fueron trasplantados; mediana de segui miento es de 8 años. Todos desarrollaron complicaciones severas post TPH, uno de ellos falleció de recaída y los tres actualmente vivos presentan un Karnofsky/Lansky 100%. Conclusión: El programa ha permitido el trasplante de 4 pacientes que de otro modo no habrían tenido acceso a un donante. Este programa de donación dirigida puede ser considerado una primera etapa para el desarrollo de un banco público de sangre de cordón umbilical en Chile.


Abstract: Introduction: Cord blood (CB) as a source of Hematopoietic Stem Cells for Transplantation (HSCT) is well established. Worldwide, nonetheless, less than 10% of the CB HSCTs are performed with a match sibling donor. Since 2004, the Chilean National Childhood Cancer Program (PINDA) net work, has established a CB directed donation program for HSCT. Patients and Method: An obser vational, descriptive and retrospective study was designed to assess the number and characteristics of the CB units collected in the program as well as the number, clinical characteristics and follow-up of the patients who received an HSCT from those CB units between January 2004 and October 2018. Results: Sixty CB units have been collected; 55 of them with full records and stored. The median volume collected was 74.8 ml (30.0-170.8), the median number of total nucleated cells was 7.6 x 10e8 (2.0-21.1), and the median of CD34+ cells was 1.6 x 10e6 (0.2-11.6). Four high-risk leukemia patients received HSCT, all of them developed severe complications after transplantation and one patient died due to relapse. Those patients currently alive have a 100% Karnofsky/Lansky score. The median follow-up time was 8 years. Conclusion: The PINDA program has allowed 4 patients to be transplan ted who otherwise would not have had access to a donor. This directed donation program could be seen as a model for the development of a public cord blood bank in Chile.


Subject(s)
Humans , Male , Female , Infant, Newborn , Infant , Child, Preschool , Child , Adolescent , Blood Donors , Hematopoietic Stem Cell Transplantation/adverse effects , Hematopoietic Stem Cell Transplantation/methods , Siblings , Directed Tissue Donation , Fetal Blood , Chile , Public Health , Retrospective Studies , Follow-Up Studies , Outcome Assessment, Health Care , National Health Programs
4.
Rev. cuba. hematol. inmunol. hemoter ; 35(4): e1092, oct.-dic. 2019. tab, graf
Article in Spanish | LILACS, CUMED | ID: biblio-1093296

ABSTRACT

Introducción: Los avances en el manejo del mieloma múltiple (MM) durante los últimos años incluyen la incorporación del trasplante de progenitores hematopoyéticos autólogo (TPHa) a la estrategia de tratamiento de estos pacientes. Objetivo: Dar a conocer los primeros resultados en el hospital Hermanos Ameijeiras (HHA) con la aplicación del TPHa en pacientes con gammapatías monoclonales (GM), empleando las altas dosis de melfalán (AD-Mel) como tratamiento acondicionante (TA) y su impacto en la sobrevida global (SG). Métodos: Se hizo un estudio retrospectivo de todos los pacientes con GM sometidos a TPHa en el Servicio de Hematología del HHA en el período comprendido entre 2009 y 2018. La muestra final comprendió 14 casos. Resultados: La edad promedio fue de 53,5 años; la mayoría tenía como diagnóstico MM (85,7 por ciento) y todos ellos debutaron en estadio III de Durie-Salmon; como TA el 64,2 por ciento recibió AD-mel, en dosis de 200 mg/m2. La recuperación de las cifras de neutrófilos y plaquetas ocurrieron como promedio a los 11,4 y 12 días, respectivamente. La mortalidad relacionada con el trasplante (MRT) al día +30 fue del 7,1 por ciento. La probabilidad de SG a los 2 años fue superior al 90 por ciento y a los 5 años del 68 por ciento. Conclusiones: Se comprobó que la realización del TPHa con el empleo de AD-Mel como TA en pacientes con GM es un proceder realizable en nuestro país con una MRT relativamente baja. Se logró demostrar que la inclusión del TPH en el tratamiento mejora considerablemente las expectativas de sobrevida de estos pacientes(AU)


Introduction: The recent advances in the management of multiple myeloma (MM) during the last years have included the autologous hematopoietic stem cell transplantation (auto-HSCT) to the treatment strategy of these patients. Objective: To present the first results in the Hermanos Ameijeiras hospital (HAH) with the application of auto-HSCT in patients with monoclonal gammopathies (MG) using high doses of melphalan (HD-Mel) as conditioning regimen (CR) and its impacton overall survival (OS). Methods: A retrospective study of all patients with MG who underwent auto-HSCT in the Hematology Service of the HAH in the period between 2009 and 2018 wasmade. The final sample comprised 14 cases. Results: The average age was 53.5 years; the majority had diagnosis of MM (85.7percent) and all of them were diagnosed in stage III of Durie-Salmon; as CR 64.2 percent received HD-mel, at 200 mg/m2. The recovery of neutrophil and platelet counts occurred on average at 11.4 and 12 days respectively. Transplant related mortality (TRM) at day +30 was 7.1 percent. The probability of OS at 2 years was higher than 90 percent and at 5 years of 68 percent. Conclusions: It was verified that the performance of auto-HSCT with the use of HD-Mel as CR in patients with MG is a feasible procedure in our country with a relatively low TRM. It was possible to demonstrate that the inclusion of auto-HSCT in the treatment considerably improves the survival expectations of these patients(AU)


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Paraproteinemias/therapy , Hematopoietic Stem Cell Transplantation/methods , Melphalan/therapeutic use , Survival Analysis , Retrospective Studies , Multiple Myeloma/therapy
5.
Rev. cuba. hematol. inmunol. hemoter ; 35(4): e1086, oct.-dic. 2019. tab
Article in Spanish | LILACS, CUMED | ID: biblio-1093294

ABSTRACT

Introducción: El trasplante relacionado de células progenitoras hematopoyéticas (TCPH) es una alternativa terapéutica curativa para los pacientes con ciertos tipos de hemopatías o de inmunodeficiencias, en la que se selecciona como donante a un familiar del receptor. Objetivo: Caracterizar el sistema de antígenos leucocitarios humanos (HLA) en receptores de TCPH relacionado. Métodos: Se realizó un estudio descriptivo y transversal en el departamento de Histocompatibilidad del Instituto de Hematología e Inmunología desde enero 2013 hasta diciembre de 2015. Se tipificaron 75 genes HLA mediante la técnica de reacción en cadena de la polimerasa con cebadores de secuencia específico, de baja resolución a 117 pacientes con criterio de TCPH. Para el análisis inmunogenético se empleó el programa Arlequín 3.5.2.2. Resultados: Fueron más frecuentes los genes HLA-A*02, HLA-B*35, HLA-DQB1*03, HLA-DRB1*03 y HLA-DRB1*04, los haplotipos de dos loci HLA-A*02 B*35, HLA-DQB1*03 DRB1*04 y el haplotipo extendido HLA-A*03 B*07 DQB1*06 DRB1*15. Conclusiones: Los genes del sistema HLA en pacientes cubanos candidatos a TCPH relacionado presentaron frecuencias similares a las descritas en poblaciones generales de Cuba y el mundo, aunque con características distintivas en algunos genes y haplotipos(AU)


Introduction: Related hematopoietic progenitor cell (TCPH) transplantation is a curative therapeutic alternative for patients with certain types of hemopathies or immunodeficiencies, in which a recipient family member is selected as a donor. Objective: To characterize the human leukocyte antigen (HLA) system in related TCPH receptors. Methods: A descriptive and cross-sectional study was conducted in the Histocompatibility department of the Institute of Hematology and Immunology from January 2013 to December 2015. 75 HLA genes were typed using the polymerase chain reaction technique with specific sequence primers, from Low resolution to 117 patients with TCPH criteria. For the immunogenetic analysis, the Harlequin 3.5.2.2 program was used. Results: The genes HLA-A * 02, HLA-B * 35, HLA-DQB1 * 03, HLA-DRB1 * 03 and HLA-DRB1 * 04, the haplotypes of two HLA-A * 02 B * 35 loci were more frequent , HLA-DQB1 * 03 DRB1 * 04 and the extended haplotype HLA-A * 03 B * 07 DQB1 * 06 DRB1 * 15. Conclusions: The genes of the HLA system in Cuban patients related to TCPH presented frequencies similar to those described in general populations of Cuba and the world, although with distinctive characteristics in some genes and haplotypes(AU)


Subject(s)
Humans , Male , Female , Polymorphism, Genetic/genetics , Hematopoietic Stem Cell Transplantation/methods , Histocompatibility Antigens/therapeutic use , Epidemiology, Descriptive , Cross-Sectional Studies , Cuba
6.
Rev. méd. Chile ; 147(12): 1561-1568, dic. 2019. tab, graf
Article in Spanish | LILACS | ID: biblio-1094190

ABSTRACT

Background The treatment of choice of newly diagnosed multiple myeloma (NDMM) is an induction with proteasome inhibitors followed autologous stem cell transplantation (HSCT). Since 2013, the treatment of these patients in the public system is based on CTD (cyclophosphamide, thalidomide, and dexamethasone). Aim To evaluate the response rates achieved with CTD, and the results of HSCT in patients with NDMM in the public setting. Material and Methods Data from patients considered as candidates for HSCT from different centers of the National Adult Antineoplastic Drug Program (PANDA, for its acronym in Spanish), diagnosed between 2013 and 2017, was analyzed. The response to treatment of first and second lines of treatment was evaluated, in addition to the results of HSCT. An optimal Response was defined as the sum of strict complete remission, complete remission and very good partial response (sCR, CR and VGPR). Results One hundred and seventy-seven patients were analyzed, 54% women, and 53% with IgG multiple myeloma. Information about the international staging system was retrieved in 127 patients (71%). Seventeen percent were ISS I, 22% in ISS II and 32% ISS III. CTD was used as first treatment in 106 patients (60%), and cyclophosphamide, bortezomib and dexamethasone (CyBorD) in 13 (7%). As first line, CTD had an overall response of 50.9%, and CyBorD of 76.9%. Thirty patients were treated with bortezomib as second line treatment. Forty patients (22%) underwent HSCT. The 5-year Overall Survival (OS) in transplanted patients and non-transplanted patients was 100 and 62% respectively (p < 0.01). Conclusions The response rate achieved by CTD in these patients is suboptimal. The response to CyBorD was better.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Hematopoietic Stem Cell Transplantation/methods , Multiple Myeloma/therapy , Time Factors , Transplantation, Autologous , Dexamethasone/administration & dosage , Antineoplastic Combined Chemotherapy Protocols , Retrospective Studies , Combined Modality Therapy , Disease-Free Survival , Cyclophosphamide/administration & dosage , Kaplan-Meier Estimate , Bortezomib/administration & dosage , Multiple Myeloma/mortality
7.
Rev. cuba. hematol. inmunol. hemoter ; 35(3): e934, jul.-set. 2019.
Article in Spanish | LILACS, CUMED | ID: biblio-1093284

ABSTRACT

En Cuba, desde en que el año 2004 se realizaron con éxito los primeros implantes de células madre hematopoyéticas adultas autólogas, se ha ido incrementando progresivamente su uso y ya se ha extendido a todo el país. En Santiago de Cuba no se disponía de un área con condiciones adecuadas para desarrollar la medicina regenerativa, lo que motivó la creación del Servicio Ambulatorio de Medicina Regenerativa (SAMERSAC) en el Banco de Sangre Provincial, donde se realiza la obtención y procesamiento de las células y la atención de los pacientes seleccionados, según los criterios de inclusión establecidos en los proyectos de investigación registrados. El SAMERSAC es un Servicio Científico Tecnológico que integra a las unidades de salud de la provincia en lo referente a líneas de investigación relacionadas con la medicina regenerativa. La creación de este nuevo servicio permitió la introducción y el inicio del desarrollo de la medicina regenerativa en Santiago de Cuba, donde se continua trabajando e investigando constantemente con la aplicación de los novedosos procedimientos que aporta esta nueva disciplina médica(AU)


In Cuba, since 2004, when the first implants of autologous adult hematopoietic stem cells were successfully performed, their use has been progressively increasing, that has already spread throughout the country. In Santiago de Cuba there was no area with adequate conditions to develop regenerative medicine, which led to the creation of the Regenerative Medicine Outpatient Service (SAMERSAC) in the Provincial Blood Bank, where it is carried out the obtaining and prosecution of the cells and the attention of the selected patients, according to the established inclusion approaches in the registered investigation projects. The SAMERSAC is a Technological Scientific Service that integrates to the units of health of the county regarding investigation lines related with the regenerative medicine. The creation of this new service allowed the introduction and the beginning of the development of the regenerative medicine in Santiago from Cuba, where you continuous working and constantly investigating with the application of the novel procedures that contributes this new discipline doctor(AU)


Subject(s)
Humans , Male , Female , Hematopoietic Stem Cell Transplantation/methods , Regenerative Medicine , Ambulatory Care/methods , Access to Essential Medicines and Health Technologies
8.
Rev. chil. pediatr ; 90(4): 443-447, ago. 2019. graf
Article in Spanish | LILACS, BNUY, UY-BNMED | ID: biblio-1020653

ABSTRACT

INTRODUCCIÓN: Osteopetrosis Infantil Maligna (OIM) es un grave e inusual desorden genético debi do a una actividad osteoclástica anormal. OBJETIVO: Reportar lactante en quien se documentó una Osteopetrosis Infantil Maligna, revisando aspectos diagnósticos y terapéuticos más relevantes. CASO CLÍNICO: Reportamos un lactante de 10 meses de sexo masculino en quien se confirmó OIM tras presentar plaquetopenia y visceromegalias. En su historial destacó ser primer hijo de padres no consanguíneos, y entre sus hallazgos presentó hepatoesplenomegalia, plaquetopenia y anemia graves, compromiso sensorial visual y auditivo e infecciones a repetición. El diagnóstico fue confirmado mediante estudio genético, el cual identificó 2 mutaciones heterocigotas en el gen TCIRG1. Se rea lizó trasplante de precursores hematopoyéticos, sin haber presentado recuperación hematológica, falleciendo por enfermedad veno oclusiva. DISCUSIÓN: La OIM es una enfermedad inusual, grave y de inicio temprano, siendo necesario un elevado índice de sospecha ante hepatoesplenomegalia y falla medular. El diagnóstico temprano y el trasplante de precursores hematopoyéticos son las únicas intervenciones potencialmente curativas de esta entidad letal.


INTRODUCCIÓN: Malignant Infantile Osteopetrosis (MIOP) is a rare and severe genetic disorder due to abnormal osteoclast activity. OBJECTIVE: To report an infant who presented Malignant Infantile Osteopetrosis, reviewing the most relevant diagnostic and therapeutic aspects. CLINICAL CASE: A ten- month-old male infant with diagnosis of MIOP confirmed after presenting thrombocytopenia and visceromegaly. He was the first child of non-consanguineous parents, and among the findings, he presented severe hepatosplenomegaly, thrombocytopenia, and anemia; visual and hearing impairment, and repeated infections. The diagnosis was confirmed by genetic study, which identified two heterozygous mutations in the TCIRG1 gene. Hematopoietic stem cells were transplanted without hematological recovery. The patient died due to occlusive venous disease. DISCUSSION: MIOP is a rare, severe, and early-onset disease, with a high rate of suspicion necessary in the presence of hepatosplenomegaly and bone marrow failure. Early diagnosis and hematopoietic stem cells transplanta tion are the only potentially therapeutic interventions of this lethal entity.


Subject(s)
Humans , Male , Infant , Osteopetrosis/diagnosis , Hematopoietic Stem Cell Transplantation/methods , Vacuolar Proton-Translocating ATPases/genetics , Osteoporosis/physiopathology , Osteoporosis/genetics , Fatal Outcome , Mutation
9.
Rev. bras. enferm ; 72(4): 994-1000, Jul.-Aug. 2019. graf
Article in English | LILACS, BDENF | ID: biblio-1020533

ABSTRACT

ABSTRACT Objective: describe the development of a virtual learning object to provide information about autologous transplantation of hematopoietic stem cells to autoimmune diseases. Methods: methodological study of a website development, using the instructional design model that includes Analysis, Design, Development and Implementation. Results: the virtual object, available at http://www.transplantardai.com.br, was developed in a web platform, in the Hypertext Markup Language, using the software WebAcappella - Responsive Website Creator (Intuisphere, France 2016). The content was structured in the modules: History, Transplant, Autoimmune Diseases, Links, Guidelines, Speech Team and Doubts. The icons and menus were created in order to attract the user, facilitating the search for information and allowing maximum use of the resources available on the website. Conclusion: the methodology used allowed the development of the virtual learning object, which can be used as a tool to guide and disseminate knowledge about this treatment.


RESUMEN Objetivo: describir el desarrollo de un objeto de aprendizaje virtual para proporcionar información sobre el trasplante autólogo de células madre hematopoyéticas en las enfermedades autoinmunes. Métodos: estudio metodológico del desarrollo del sitio web, utilizando el modelo de diseño instruccional (Análisis, Diseño, Desarrollo e Implementación). Resultados: el objeto virtual, disponible en http://www.transplantardai.com.br, fue desarrollado en una plataforma web, en el lenguaje de marcación Hypertext Markup Language, utilizando el software WebAcappella - Responsive Website Creator (Intuisphere, Francia 2016). El contenido se estructuró en los módulos: Historia, Trasplante, Enfermedades Autoinmunes, Links, Guías, Habla Equipo y Dudas. Los iconos y menús fueron creados para atraer al usuario, facilitando la búsqueda de información y permitiendo el máximo aprovechamiento de los recursos disponibles en el sitio web. Conclusión: la metodología utilizada permitió el desarrollo del objeto de aprendizaje virtual, que puede ser utilizado como una herramienta para guiar y difundir el conocimiento sobre este tratamiento.


RESUMO Objetivo: descrever o desenvolvimento de um objeto virtual de aprendizagem para disponibilização de informações sobre transplante autólogo de células-tronco hematopoéticas para doenças autoimunes. Métodos: estudo metodológico de desenvolvimento de um website, empregando o modelo de design instrucional que envolve Análise, Design, Desenvolvimento e Implementação. Resultados: o objeto virtual, disponível no endereço eletrônico http://www.transplantardai.com.br, foi desenvolvido em plataforma web, na linguagem de marcação Hypertext Markup Language, utilizando-se o software WebAcappella - Responsive Website Creator (Intuisphere, França 2016). O conteúdo foi estruturado nos seguintes módulos: História, Transplante, Doenças Autoimunes, Links, Orientações, Fala Equipe e Dúvidas. Os ícones e menus foram criados de modo a atrair o usuário, facilitando a busca de informações e permitindo máximo uso dos recursos disponíveis no website. Conclusão: a metodologia empregada permitiu o desenvolvimento do objeto virtual de aprendizagem, que poderá ser utilizado como ferramenta para orientar e disseminar o conhecimento sobre esse tratamento.


Subject(s)
Humans , Autoimmune Diseases/therapy , Problem-Based Learning/methods , Hematopoietic Stem Cell Transplantation/instrumentation , Hematopoietic Stem Cell Transplantation/methods , Virtual Reality , Autoimmune Diseases/complications , Problem-Based Learning/standards , France
10.
Arq. neuropsiquiatr ; 77(8): 531-535, Aug. 2019. tab, graf
Article in English | LILACS | ID: biblio-1019472

ABSTRACT

ABSTRACT Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system. Its treatment has focused on inflammation control as early as possible to avoid disability. Autologous hematopoietic stem cell transplantation (AHSCT) has been used for treating MS since 1996, with recent decisive results regarding benefits in long-term efficacy. Five patients followed up at an MS center in Belo Horizonte, Brazil, who had relapsing-remitting MS with high disease activity, underwent AHSCT between 2009 and 2011. They were evaluated clinically, with magnetic resonance imaging, and by the EDSS every six months after transplantation, up to July 2018. The patients were four women and one man, with ages ranging from 25-50 years, and time since disease onset ranging from 4-17 years at the time of the procedure. Four patients improved, one patient was stabilized, and all patients were free of disease activity after 5-9 years. Through improving patient selection and decreasing the time from disease onset, AHSCT could stop epitope spreading and disease progression. Despite multiple other therapeutic choices being approved for relapsing-remitting MS, AHSCT continues to be a treatment to consider for aggressive MS disease.


RESUMO A esclerose múltipla é uma doença imunomediada do sistema nervoso central. Seu tratamento tem sido focado no controle da inflamação o mais cedo possível para evitar incapacidade. O transplante autólogo de células tronco hematopoiéticas (TACTH) vem sendo usado para tratar esclerose múltipla desde 1996, e recentes resultados foram decisivos a respeito do benefício na eficácia a longo prazo. Cinco pacientes seguidos num centro de esclerose múltipla de Belo Horizonte, Brasil, que apresentavam forma clínica remitente recorrente com alta atividade de doença foram submetidos a esse tratamento de 2009 a 2011. Após o transplante foram avaliados clinicamente e com ressonância magnética, e escala de EDSS, a cada seis meses até julho de 2018. Os pacientes eram quatro mulheres e um homem, com idade entre 25 e 50 anos e tempo de doença variando de 4 a 17 anos na época do procedimento. Quatro pacientes melhoraram após a primeira avaliação e um manteve-se estável. Todos os pacientes permaneceram sem evidência de doença clínica ou radiológica de 5 a 9 anos após. Com uma seleção cada vez mais criteriosa de pacientes o TACTH pode interromper a disseminação do epítopo e controlar a progressão da doença. Apesar de várias outras opções terapêuticas aprovadas para esclerose múltipla o TACTH continua a ser uma forma de tratamento a ser considerada em casos de doença muito agressiva.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Young Adult , Hematopoietic Stem Cell Transplantation/methods , Multiple Sclerosis, Relapsing-Remitting/surgery , Follow-Up Studies , Treatment Outcome , Disease Progression , Disability Evaluation
11.
Rev. méd. Chile ; 147(4): 437-443, abr. 2019. tab, graf
Article in Spanish | LILACS | ID: biblio-1014244

ABSTRACT

Background: Hodgkin lymphoma has a high rate of curability, even in advanced stages. Aim: To assess the results of Hodgkin lymphoma treatment using the ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy regimen. Material and Methods: Analysis of a database held by the Chilean Ministry of Health, including all patients treated at accredited cancer treatment centers. Results: Data for 915 patients, median age 35 years (range 15-86 years) and followed for a median of 97 months (range 1-347 months) were analyzed. Forty-one percent had localized disease. Overall survival at five years for localized and advanced stages was 92% and 74%, respectively. The figures for progression free survival were 87% and 64%, respectively. Patients with relapse who received autologous stem cell transplantation (ASCT) had a five year overall survival of 92%, compared to 64% among those who did not undergo this procedure (p < 0.01). The Guarantees in Health Program set up by the Ministry of Health, was associated with earlier stage disease at diagnosis. Conclusions: The ABVD regimen achieves high rates of cure in localized stages of the disease but the results in advanced stages are not optimal. ASCT significantly improves survival in patients with relapse. The Guarantees in Health Program is associated with earlier diagnosis of the disease.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Aged , Aged, 80 and over , Young Adult , Hodgkin Disease/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Time Factors , Vinblastine/therapeutic use , Bleomycin/therapeutic use , Hodgkin Disease/mortality , Hodgkin Disease/pathology , Doxorubicin/therapeutic use , Chile , Treatment Outcome , Hematopoietic Stem Cell Transplantation/methods , Disease-Free Survival , Dacarbazine/therapeutic use , Kaplan-Meier Estimate
12.
Int. braz. j. urol ; 45(1): 74-82, Jan.-Feb. 2019. tab, graf
Article in English | LILACS | ID: biblio-989965

ABSTRACT

ABSTRACT Purpose: The current first - line treatment for non - seminomatous germ cell tumor (NSGCT) consists of four cycles of cisplatin, etoposide, and bleomycin (BEP), which results in 5 - year overall survival < 60% in patients with poor - risk features. Autologous hematopoietic stem cell transplantation (auto - HSCT) as a method for overcoming high toxicity after high dose chemotherapy (HDC) has been explored in different solid tumors, but has remained standard practice only for NSGCT. Our objective was to describe outcomes of patients with poor - risk NSGCT who underwent first - line autologous HSCT in a tertiary center in Mexico. Patients and Methods: Twenty nine consecutive patients with NSGCT who received first - line, non - cryopreserved autologous HSCT at the National Institute of Medical Sciences and Nutrition Salvador Zubiran in Mexico City, Mexico, from November 1998 to June 2016, were retrospectively analyzed. Results: The median age at transplantation was 23 (15 - 39) years. Most patients (n = 18, 62%) had testicular primary tumor, and 23 had metastases (79%). Complete response after auto - HSCT was observed in 45%. Non - relapse mortality was 0. Five - year relapse / progression free and overall survival were 67% and 69%, respectively. Conclusions: This small single limited - resource institution study demonstrated that patients with poor - risk NSGCT are curable by first - line HDC plus autologous HSCT and that this procedure is feasible and affordable to perform using non - cryopreserved hematopoietic stem cells.


Subject(s)
Testicular Neoplasms/therapy , Bleomycin/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Cisplatin/administration & dosage , Neoplasms, Germ Cell and Embryonal/therapy , Hematopoietic Stem Cell Transplantation/methods , Etoposide/administration & dosage , Retrospective Studies , Treatment Outcome , Combined Modality Therapy , Kaplan-Meier Estimate
13.
Rev. méd. Chile ; 147(1): 9-17, 2019. tab, graf
Article in Spanish | LILACS | ID: biblio-991367

ABSTRACT

Background: Mantle cell lymphoma (MCL) has high relapse and mortality rates. There is a survival benefit when treatment is intensified with cytarabine (AraC), hematopoietic cell transplantation (HCT) and maintenance with rituximab. Aim: To assess the outcomes of patients with MCL treated in a university hospital. Material and Methods: Review of an oncology center database and medical records identifying patients with MCL treated between 2006 and 2017. Death dates were obtained from the death certificate database of the National Identification Service. We analyzed the response rate, overall survival (OS) and progression-free survival (PFS). As a secondary objective, the survival impact of AraC, HCT and maintenance with rituximab, was also analyzed. Results: Information on 20 patients aged 62 ± 11 years, followed for a median of 45 months was retrieved. Eighty-five percent were diagnosed at an advanced stage. The most used first-line regime was R-CHOP in 11 patients, followed by R-HyperCVAD in five. Only 47% achieved complete response. 4-year PFS and OS were of 30 and 77% respectively. Mantle Cell Lymphoma International Prognostic Index (MIPI) significantly predicted PFS and OS. Maintenance with rituximab or HCT was associated with better PFS (48 vs 21 months, p < 0.01). The exposure to AraC or HCT, in refractory or relapsed disease, was associated with an increase in PFS from 9 to 28 months (p = 0,02) and 4-year OS from 40 to 100% (p = 0.05). OS increased even more, from 25 to 100% in those with high-risk MIPI (p = 0.04). Conclusions: The incorporation of AraC, HCT and maintenance with rituximab in the therapeutic backbone of MCL, especially for high-risk cases, was associated with improved survival.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Hematopoietic Stem Cell Transplantation/methods , Lymphoma, Mantle-Cell/surgery , Lymphoma, Mantle-Cell/drug therapy , Cytarabine/therapeutic use , Rituximab/therapeutic use , Antineoplastic Agents, Immunological/therapeutic use , Antimetabolites, Antineoplastic/therapeutic use , Time Factors , Retrospective Studies , Risk Factors , Treatment Outcome , Sex Distribution , Combined Modality Therapy , Age Distribution , Statistics, Nonparametric , Lymphoma, Mantle-Cell/mortality , Kaplan-Meier Estimate , Progression-Free Survival , Neoplasm Recurrence, Local
14.
Article in English | LILACS, BDENF | ID: biblio-978630

ABSTRACT

ABSTRACT Objective: to know the care provided by family caregivers of children submitted to hematopoietic stem cell transplantation. Method: the Grounded Theory was used as methodology. The study comprised four sample groups, comprising 36 caregivers. Data were collected by semi-structured interviews and analyzed according to the coding proposed by Strauss and Corbin in three phases: open, axial and selective. Results: eight propositions were identified for the care provided to the child in the researched context, namely administering medications; attention to cleaning issues; care with water and food intake; care with the body; experiencing protective isolation; addressing the child's need for emotional support; addressing the child's self-care; and facing complications. Conclusion: the different aspects in which the caregiver acts in the care of the child were understood. Such care equips the health team to elaborate measures for guidance and preparation of home care that are effective and directed to the needs of the patient and their family. The understanding of the care that they accomplish enables the caregiver a greater understanding of their role, as well as of the decisions they will make by their being under treatment.


RESUMO Objetivo: conhecer os cuidados realizados pelo cuidador familiar da criança em pós-transplante de células-tronco hematopoiéticas. Método: utilizou-se a Grounded Theory como metodologia; compreendendo quatro grupos amostrais, perfazendo 36 cuidadores; com dados coletados por entrevistas semiestruturadas. Os dados foram analisados segundo a codificação proposta por Strauss e Corbin, em três fases: aberta, axial e seletiva. Resultados: foram identificadas oito proposições para os cuidados realizados com criança no contexto pesquisado: administrar medicações; atentar às questões de limpeza; cuidados com ingesta hídrica e alimentar; cuidados com o corpo; experienciar o isolamento protetor; trabalhar a necessidade de apoio emocional da criança; abordar o autocuidado da criança; e encarar complicações. Conclusão: compreenderam-se as diferentes vertentes em que o cuidador atua no cuidado com a criança. Esses cuidados instrumentalizam a equipe de saúde ao nortear a elaboração de medidas de orientação e preparo para o cuidado domiciliar que sejam efetivas e direcionadas às necessidades do paciente e da família. A compreensão dos cuidados que realiza viabiliza ao cuidador maior entendimento do seu papel, bem como das decisões que tomará pelo seu ente em tratamento.


RESUMEN Objetivo: conocer los cuidados realizados por el cuidador familiar del niño después del trasplante de células madre hematopoyéticas. Método: se utilizó la Grounded Theory como metodología; comprendió cuatro grupos de muestreo, totalizando 36 cuidadores; utilizó datos recogidos por medio de entrevistas semiestructuradas, los datos fueron analizados según la codificación propuesta por Straus y Corbin, en tres fases: abierta, axial y selectiva. Resultados: fueron identificadas ocho proposiciones para los cuidados realizados al niño en el siguiente contexto investigado: administrar medicaciones; prestar atención a las cuestiones de limpieza; cuidados con ingesta hídrica y alimentar; cuidados con el cuerpo; experimentar el aislamiento protector; trabajar la necesidad de dar apoyo emocional al niño; abordar el autocuidado del niño; y, encarar las complicaciones. Conclusión: fueron comprendidas las diferentes vertientes en las cuales el cuidador actúa en el cuidado al niño. Esos cuidados instrumentalizan al equipo de salud para orientar la elaboración de medidas de orientación y preparación, para el cuidado domiciliar, que sean efectivas y dirigidas a las necesidades del paciente y su familia. La comprensión de los cuidados que realiza viabiliza al cuidador obtener mayor entendimiento de su papel, así como de las decisiones que tomará auxiliar a su familiar en tratamiento.


Subject(s)
Humans , Male , Female , Child , Adult , Bone Marrow Transplantation/methods , Hematopoietic Stem Cell Transplantation/methods , Child Care/psychology , Caregivers/psychology , Housing
15.
Rev. habanera cienc. méd ; 17(6): 943-948, nov.-dic. 2018. graf
Article in Spanish | LILACS, CUMED | ID: biblio-991299

ABSTRACT

Introducción: Las fracturas de cadera son muy frecuentes en el anciano, la primera fase de consolidación de una fractura es el hematoma creado a este nivel, si éste se enriquece con células madre adultas autólogas podría disminuir el tiempo de consolidación de la fractura debido a la gran capacidad que tienen estas células para transformarse en otros tipos de tejido. Objetivo: Evidenciar las ventajas del implante de las células madre en un paciente con fractura reciente de cadera. Presentación del caso: paciente con fractura de cadera que se operó en las primeras 24 horas y que durante su intervención se le implantaron células monoculares (células madre) obtenidas de su pelvis. Conclusiones: Se demostró la factibilidad de dicho proceder y la buena evolución del paciente, sin complicaciones y una consolidación precoz(AU)


Introduction: Hip fractures are very common in the elderly. It is known that the first phase of fracture healing is a local hematoma, and if it is enriched with autologous stem cells, hip fracture healing time could be diminished due to the great capacity these cells have to turn into other types of tissues. Objective: To show the advantages of the stem cells implant in a patient with a hip fracture Case presentation: A patient with a hip fracture underwent surgery during the first 24 hours after fracture and during the surgical procedure, monocular stem cells obtained from his pelvis were implanted. Conclusions: The feasibility of the stem cells implant in a hip fracture without complications and earlier healing was demonstrated(AU)


Subject(s)
Hematopoietic Stem Cell Transplantation/methods , Hip Fractures/therapy , Cell Transplantation
18.
Rev. cuba. hematol. inmunol. hemoter ; 34(2): 116-124, abr.-jun. 2018.
Article in Spanish | LILACS, CUMED | ID: biblio-978417

ABSTRACT

La predisposición de algunas familias a padecer hemopatías mieloides malignas ha sido descrita desde hace varias décadas; sin embargo, solo recientemente ha sido posible conocer las bases moleculares de estos síndromes. La importancia de reconocer y diagnosticar la presencia de mutaciones predisponentes de la línea germinal en pacientes con hemopatías malignas y en sus familiares determinó que la Organización Mundial de la Salud (OMS) introdujera esta nueva categoría en su última revisión de la clasificación de las neoplasias malignas y leucemias agudas. Mediante el uso de las modernas técnicas de biología molecular se ha logrado el descubrimiento de mutaciones en diferentes genes que aportan nuevos elementos en el proceso de leucemogénesis, permiten ofrecer consejo genético, una mejor selección del donante de médula ósea y se erigen en la fuente de futuras dianas terapéuticas. En este trabajo se revisan algunos de los síndromes de hemopatías mieloides malignas hereditarias (HMMH) y se enfatiza en la necesidad de realizar una exhaustiva historia clínica personal y familiar que permita un elevado índice de sospecha para el diagnóstico de estas entidades(AU)


The familial predisposition to inherited myeloid malignancies has been described since several decades ago; however, only recently have been possible to known the molecular basis of these syndromes. The importance to recognize and diagnosed predisposing germ line mutations in patients and relatives contributed to the introduction of this new category in the latest update of myeloid neoplasm and acute leukemia by World Health Organization (WHO). The use of modern molecular biology techniques has achieved the discovery of genetic mutations that shed light inside leukemogenesis process, allow offering a genetic counseling, a better donor selection and are the basis of future therapeutics targets. The main hereditary myeloid malignancy syndromes (IMMS) are reviewed, emphasizing the need of exhaustive personal and family clinical history and to have a high suspicion index to diagnose these entities(AU)


Subject(s)
Humans , Hematopoietic Stem Cell Transplantation/methods , Hematologic Neoplasms/diagnosis , Hematologic Neoplasms/genetics , Medical Records/standards , Germ-Line Mutation/genetics
20.
Rev. Soc. Bras. Clín. Méd ; 16(1): 64-69, 20180000.
Article in Portuguese | LILACS | ID: biblio-885011

ABSTRACT

O linfoma folicular é um tipo de linfoma não Hodgkin de células B indolente. Apenas 30% dos pacientes apresentam doença em fase inicial ao diagnóstico. Os pacientes com estadiamento III-IV estão entre a maioria dos diagnósticos da doença e apresentam altas taxas de recaída ou refratariedade ao tratamento. O linfoma folicular recaído ou refratário permanece um desafio para a prática clínica. O transplante de células-tronco hematopoéticas autólogo vem sendo utilizado há muito tempo nesse perfil de pacientes, com altos índices de complicações como segunda neoplasia e curto período de remissão. O transplante de células-tronco hematopoéticas alogênico com regime de condicionamento mieloablativo apresenta resultados pouco aceitáveis, devido ao aumento da mortalidade relacionada ao tratamento sem benefícios em sobrevida global, da sobrevida livre de doença ou da taxa de recaída que sustentem tal indicação O transplante de células-tronco hematopoéticas alogênico com regime de condicionamento com intensidade reduzida parece ser uma alternativa promissora, inclusive como primeiro transplante. Alguns estudos comparando os resultados dos três tipos de transplantes em pacientes com linfoma folicular recaído ou refratário, com enfoque principal no transplante de células-tronco hematopoéticas alogênico de condicionamento com intensidade reduzida, são descritos neste artigo de revisão.(AU)


Follicular Lymphoma is a type of indolent B-cell non-Hodgkin´s lymphoma. Only 30% of the patients present with an early phase of the disease at diagnosis. Patients with stage III-IV are among the majority of the diagnoses of the disease, and these have high rates of relapse or refractoriness to treatment. Relapsed or refractory follicular lymphoma remains a challenge for clinical practice. Autologous hematopoietic stem cell transplantation has been used for a long time in this profile of patients, with high rates of complications, such as second neoplasia and short remission period. The allogenic hematopoietic stem cell transplantation with myeloablative conditioning regimen presents poorly acceptable results due to increased treatment-related mortality with no overall survival benefits, disease-free survival, or relapse rate to warrant it. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen seems to be a promising alternative, even as the first transplant. Some studies comparing the results of the three types of transplants in patients with relapsed or refractory follicular lymphoma , with a main focus on hematopoietic stem cell transplantation allogenic with reduced-intensity conditioning regimen, will be described in this review article.(AU)


Subject(s)
Humans , Male , Female , Antibiotics, Antineoplastic/administration & dosage , Hematopoietic Stem Cell Transplantation/methods , Lymphoma, Follicular/pathology , Lymphoma, Follicular/therapy , Transplantation, Autologous/methods
SELECTION OF CITATIONS
SEARCH DETAIL